Study On Correlation Between The Expressions Of ER, PR, P53, Her-2 And The Effect Of Neoadjuvant Chemotherapy In Breast Cancer

Objective:To investigate the correlation of ER,PR,p53 and Her-2 expression in breast cancer with the response to neoadjuvant chemotherapy,and to search for biological markers to predict the effect of neoadjuvant chemotherapy before therapy.Methods:The data of 114 female patients with Stageâ…¡A-â…¢C breast cancer was retrospectively analyzed.These patients with age from 27 to 70 were enrolled into the Department of Surgical Oncology,the 2nd Affiliated Hospital of Zhejiang University School of Medicine from January 2007 to February 2009.All patients with non-metastasis tumors were received neoadjuvant chemotherapy with two to six cycles of FEC(5-fluorouracil,epirubicin and cyclophosphamide) or TE(docetaxel and epirubicin) regimen before operation.All tumors were identified by core needle biopsy and the expressions of ER,PR,p53 and Her-2 were detected by immunohistochemical method before neoadjuvant chemotherapy.Response rate was evaluated after neoadjuvant chemotherapy and the relationship between the expressions of biomarkers and the effect of neoadjuvant chemotherapy was analyzed with the help of SPSS FOR WINDOWS 16.0.Results:Among the 114 cases of neoadjvant chemotherapy,the positive expression rate of ER,PR,p53 and Her-2 was 55.3%,49.1%,41.2%and 26.3%,respectively.The clinical response rate(complete response[CR]plus partial response[PR]) of neoadjuvant chemotherapy with FEC or TE was 66.7%(63/114),with CR 11.4%(13/114),PR 55.3%(63/114),SD 30.7%(35/114),PD 2.6%(3/114).In this study,pathological complete response was found in 4 cases(3.5%).In the differences of the clinical response rate between ER negative and ER positive,PR negative and PR positive,p53 negative and p53 positive,tHere were statistical significance(p<0.05).However,there was no significant difference between the response rate and Her-2 status(p>0.05).Conclusion:In the patients with breast cancer,ER,PR and p53 negative tumors are more sensitive to FEC or TE regimen neoadjuvant chemotherapy.These patients may get more benefits from neoadjuvant chemotherapy.Therefore,ER,PR and p53 can be considered as predictive markers of the effect of neoadjuvant chemotherapy with FEC or TE regimen.